Fiche du document
- doi: 10.1016/j.neurol.2024.03.003
- issn: 0035-3787
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.neurol.2024.03.003
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/38580500
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/0035-3787
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_C7869E274C5A2
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2025-05-31 , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
illnessCiter ce document
N. Déglon, « Gene editing as a therapeutic strategy for spinocerebellar ataxia type-3. », Serveur académique Lausannois, ID : 10.1016/j.neurol.2024.03.003
Métriques
Partage / Export
Résumé
Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, is a neurodegenerative disease caused by expanded polyglutamine repeats in exon 10 of the ataxin-3 gene, ATXN3. The accumulation of mutant ATXN3 protein leads to severe clinical manifestations and premature death. Clinically, SCA3 pathology is characterized by progressive ataxia leading to motor incoordination that may affect balance, gait and speech, and neuropathologically by a progressive degeneration of the spinal cord and cerebellum, as well as the cerebral cortex and basal ganglia. Although SCA3 is a rare disease, it is the most common autosomal dominant spinocerebellar ataxia worldwide. Its geographical distribution varies worldwide, with peak prevalence in certain regions of Brazil, Portugal and China. In 1994, the identification of the polyglutamine expansion in the ATXN3 gene made it possible not only to diagnose this pathology but also to dissect the mechanisms leading to cellular degeneration. As a monogenic disease for which only symptomatic treatment is available, the ATXN3 gene represents an attractive therapeutic target for gene editing strategies.
